DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...

A 64-year-old long-distance runner, Todd Elworthy was alarmed and confused when his routine prostate specific antigen (PSA) test was elevated in 2023, and a biopsy came back positive for prostate ...

"Grey’s Anatomy" veteran James Pickens Jr. is opening up about his own real-life health diagnosis. Following the Thursday, Nov. 13 midseason finale episode, ABC aired a public service announcement ...

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current hormone therapies for prostate cancer and benign prostatic hyperplasia (BPH ...

When "Dilbert" creator Scott Adams recently made a public plea for help accessing a life-extending cancer treatment, the story drew national attention — and sparked some questions about the drug ...

Although overall quality of life was not improved with app support, use of the app had a positive effect on bowel symptoms 3 weeks after treatment. A specialized app that helps with symptom monitoring ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Prostate cancer is an issue that impacts patients differently. Thankfully, their different treatment options help patients in the best way they see fit. Dr. Jose Avitia, a medical oncologist with the ...

Former President Joe Biden has completed a course of radiation therapy after being diagnosed in May with an "aggressive form" of prostate cancer, according to a spokesperson. Biden's daughter Ashley ...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...